Opko Health, Inc. (NYSE:OPK)

CAPS Rating: 1 out of 5

Recs

4
Player Avatar zzlangerhans (99.78) Submitted: 8/15/2008 2:12:44 AM : Underperform Start Price: $1.85 OPK Score: -254.67

The huge float makes Opko seem deceptively cheap. But 350M for a completely unproven siRNA therapy with a scam artist like Philip Frost at the wheel is definitely not cheap. Why anyone entrusts this guy with an investment after disasters like Protalix is a mystery to me.

Report this Post 2 Replies
Member Avatar acodalbu (65.66) Submitted: 8/19/2009 1:23:11 PM
Recs: 0

Protalix isnt a disaster for me... bought at 2$ and now ive tripled up, and followed Dr Frost to OPK... Well see who laughs last

Report this Post
Member Avatar kkcajj (< 20) Submitted: 12/10/2010 3:20:29 PM
Recs: 4

I don't think some of the investors have ever looked into the history of Dr Frost. He has been very successful in at least two companies that he has started. To say he is anything other than a success story is very false.

Report this Post

Featured Broker Partners


Advertisement